Explanipedia

Increased 1-deoxySphingolipids caused by an altered plasma Alanine to Serine ratio are associated with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Open

F. Wipfli, Museer A. Lone, Arnold von Eckardstein, An Verrijken, Sven Francque , et al. · 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (formerly Non-Alcoholic Fatty Liver Disease, NAFLD) encompasses a spectrum of metabolic disorders ranging from isolated steatosis to Metabolic Dysfunction-Associated Steatohe…

Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration Open

Evelien Van Dijck, Steven Van Laere, Emilie Logie, Steven Timmermans, Erik Fransén , et al. · 2025

Gradual DNAm changes were found to align with progression of MASLD and EAA, with EAA a potential nonbiased quantitative biomarker for MASLD. Integrative analysis highlighted potential new therapeutic transcription factor targets, with spec…

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes Open

Oliver Schnell, Jaime P. Almandoz, Lisa Anderson, Katharine Barnard‐Kelly, Tadej Battelino , et al. · 2025

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5–6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered o…

Cardio‐renal‐metabolic disease in primary care setting Open

Mahmoud Ibrahim, Ebtesam Ba-Essa, Jason Baker, Avivit Cahn, Antonio Ceriello , et al. · 2023

In the primary care setting providers have more tools available than ever before to impact positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is important to recognise what is available for treatm…

The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα Open

Ludivine Clavreul, Lucie Bernard, Alexia K. Cotte, Nathalie Hennuyer, Cyril Bourouh , et al. · 2023

Rare Heterozygous PCSK1 Variants in Human Obesity: The Contribution of the p.Y181H Variant and a Literature Review Open

Evelien Van Dijck, Sigri Beckers, Sara Diels, Tammy Huybrechts, An Verrijken , et al. · 2022

Recently, it was reported that heterozygous PCSK1 variants, causing partial PC1/3 deficiency, result in a significant increased risk for obesity. This effect was almost exclusively generated by the rare p.Y181H (rs145592525, GRCh38.p13 NM_…

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis Open

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luís M. Ruilope , et al. · 2022

OBJECTIVE Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taki…

Unsupervised Exercise Training Was Not Found to Improve the Metabolic Health or Phenotype over a 6-Month Dietary Intervention: A Randomised Controlled Trial with an Embedded Economic Analysis Open

Wendy Hens, Dirk Vissers, Nick Verhaeghe, Jan Gielen, Luc Van Gaal , et al. · 2021

Ectopic fat leads to metabolic health problems. This research aimed to assess the effectiveness of a hypocaloric diet intervention together with an unsupervised exercise training program in comparison with a hypocaloric diet alone to reduc…

Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity Open

Maxime Nachit, Wilhelmus J. Kwanten, Jean‐Paul Thissen, Bart Op de Beeck, Luc Van Gaal , et al. · 2021

NASH-related increases in plasma bile acid levels depend on insulin resistance Open

Guillaume Grzych, Oscar Chávez‐Talavera, Amandine Descat, Dorothée Thuillier, An Verrijken , et al. · 2020

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis Open

Wim Verlinden, Eugénie Van Mieghem, Laura Depauw, Thomas Vanwolleghem, Luisa Vonghia , et al. · 2020

The incidence of non-alcoholic fatty liver disease (NAFLD) is rising across the globe, with the presence of steatohepatitis leading to a more aggressive clinical course. Currently, the diagnosis of non-alcoholic steatohepatitis (NASH) is b…

Tackling obesity during the COVID‐19 pandemic Open

Amit Akirov, Avivit Cahn, Stefano Del Prato, Philip Home, Luc Van Gaal , et al. · 2020

All authors have no conflict of interest relevant to this paper to declare. This is a review and not a study involving human or animal studies, therefore ethics approval was not required. Amit Akirov and Avivit Cahn drafted the manuscript.…

Active non-alcoholic steatohepatitis and severe fibrosis are associated to dysfunctional adipose tissue and worsen with adipose tissue insulin resistance independently of body mass index Open

Luisa Vonghia, Melania Gaggini, An Verrijken, Jonas Weyler, Fabrizia Carli , et al. · 2020

Myosteatosis is associated with early NASH in the context of obesity and metabolic syndrome Open

Maxime Nachit, Greetje Vande Velde, Wilhelmus J. Kwanten, Jean‐Paul Thissen, Maxime De Rudder , et al. · 2020

Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome Open

Ahmad Moolla, Jasper de Boer, David Pavlov, Amin Amin, Angela E. Taylor , et al. · 2020

Summary Background The development of accurate, non‐invasive markers to diagnose and stage non‐alcoholic fatty liver disease (NAFLD) is critical to reduce the need for an invasive liver biopsy and to identify patients who are at the highes…

Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent Open

Guillaume Grzych, Luisa Vonghia, Marie-Adélaïde Bout, Jonas Weyler, An Verrijken , et al. · 2020

Context Plasma branched chain amino acid (BCAA) concentrations correlate positively with body mass index (BMI), measures of insulin resistance (IR), and severity of nonalcoholic fatty liver disease (NAFLD). Moreover, plasma BCAA concentrat…

Author response for "Features of oral glucose tolerance test in patients after Roux‐en‐Y gastric bypass with and without hypoglycaemia symptoms in daily life: it's all about speed" Open

Ilke Mariën, Christophe De Block, An Verrijken, Kristof Van Dessel, Frida Peiffer , et al. · 2020

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program Open

Toshiaki Ohkuma, Luc Van Gaal, Wayne Shaw, Kenneth W. Mahaffey, Dick de Zeeuw , et al. · 2019

Aims Sodium glucose co‐transporter 2 (SGLT2) inhibitors reduce several cardiovascular risk factors, including plasma glucose, blood pressure, albuminuria and body weight. Long‐term treatment lowers risks of cardiovascular and renal events.…

Author Correction: Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution Open

Joel T. Haas, Luisa Vonghia, Denis A. Mogilenko, An Verrijken, Olivier Molendi‐Coste , et al. · 2019

Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution Open

Joel T. Haas, Luisa Vonghia, Denis A. Mogilenko, An Verrijken, Olivier Molendi‐Coste , et al. · 2019

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity Open

Philip N. Newsome, Sven Francque, Stephen A. Harrison, Vlad Ratziu, Luc Van Gaal , et al. · 2019

Summary Background Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. Aim To ev…

Cardiometabolic importance of 1-h plasma glucose in obese subjects Open

Lien Haverals, Kristof Van Dessel, An Verrijken, Eveline Dirinck, Frida Peiffer , et al. · 2019

Background/objectives To study the importance and clinical usefulness of the 1-h plasma glucose (1hPG) in a Caucasian obese population with regard to the presence of prediabetes, diabetes, and metabolic syndrome (MetS). Subjects/methods We…

Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα Open

Ning Liang, Anastasius Damdimopoulos, Saioa Goñi, Zhiqiang Huang, Lise‐Lotte Vedin , et al. · 2019

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study Open

Luc Van Gaal, Michel P. Hermans, Evis Daci, Kris Denhaerynck, Lut De Meester , et al. · 2019

Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα Open

Ning Liang, Anastasius Damdimopoulos, Saioa Goñi, Marco Giudici, Zhiqiang Huang , et al. · 2019

Obesity triggers the genesis of non-alcoholic fatty liver diseases (NAFLD), which involves alterations of regulatory transcription networks and of hepatocyte-selective epigenomes. Here we demonstrate that G protein pathway suppressor 2 (GP…

Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα Open

Ning Liang, Anastasius Damdimopoulos, Saioa Goñi, Marco Giudici, Zhiqiang Huang , et al. · 2019

Obesity triggers the genesis of non-alcoholic fatty liver diseases (NAFLD), which involves alterations of regulatory transcription networks and of hepatocyte-selective epigenomes. Here we demonstrate that G protein pathway suppressor 2 (GP…

Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects Open

Kaat Kehoe, Heidi Noels, Wendy Theelen, Emilie De Hert, Shenguan Xu , et al. · 2018

Our novel findings demonstrate that white blood cells and plasma contributed the most to circulating PRCP activity. Additionally, we have shown that there were significant correlations between serum PRCP activity and various metabolic para…

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes Open

W. Timothy Garvey, Luc Van Gaal, Lawrence A. Leiter, Ujjwala Vijapurkar, James F. List , et al. · 2018

These results indicate that canagliflozin may improve adipose tissue function and induce changes in serum leptin, adiponectin, and IL-6 that favorably impact insulin sensitivity and cardiovascular disease risk.

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial Open

Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C. Griffen , et al. · 2017

Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects Open

Vanessa Legry, Sven Francque, Joel T. Haas, An Verrijken, Sandrine Caron , et al. · 2017

In obese patients, BA alterations are related to the metabolic phenotype associated with NASH, especially IR, but not liver necroinflammation.

Luc Van Gaal YOU? Author Swipe